SCHEMBL648899

SCHEMBL648899

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc2c(c1)CCC(=O)N2)CC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
HTR1A P08908 3/20 0.34
DRD2 P14416 3/20 0.34
HTR2A P28223 3/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
DRD4 P21917 1/20 0.34
HTR2C P28335 1/20 0.34
SLC6A4 P31645 1/20 0.34
HTR7 P34969 1/20 0.34
DRD3 P35462 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
BRD4 O60885 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HDAC1 Q13547 1/20 0.33
MAOA P21397 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648380 0.92 CRHR1 (0.37) C5AR1HTR1ADRD2HTR2APDE3B
SCHEMBL651748 0.89 C5AR1 (0.44) C5AR1HTR1ADRD2HTR2ADRD4
SCHEMBL650841 0.89 C5AR1 (0.44) C5AR1HTR1ADRD2HTR2ADRD4
SCHEMBL652148 0.88 C5AR1 (0.41) C5AR1LMNATSHRKDM4EALDH1A1
SCHEMBL649695 0.84 C5AR1 (0.59) C5AR1HTR1ADRD2HTR2ADRD4
SCHEMBL5135713 0.83 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5137864 0.83 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL1912836 0.83 C5AR1 (0.39) C5AR1HTR1ADRD2HTR2APDE3B
SCHEMBL5134910 0.82 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5134999 0.82 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed